Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Endocyte Inc.

www.endocyte.com

Latest From Endocyte Inc.

Narasimhan: Novartis' Specialized Portfolio Will Lead To Bigger Breakthroughs And Greater Value

At Novartis’s first R&D day since he took the helm, new CEO Vas Narasimhan told Scrip about how the company plans to build value through its newly acquired breakthrough technologies and what deals it is looking for next.

Business Strategies Commercial

Deal Watch, M&A: Warp Drive And Its Partnerships Acquired By Revolution

Once expected to be absorbed by Sanofi, US biotech Warp Drive Bio now will become part of California’s Revolution Medicines in a stock transaction. Sosei elects against its option to acquire MiNA Therapeutics; MeiraGTX follows its June IPO with takeout of Vector Neurosciences. Other recent mergers and acquisitions... 

M & A Deals

Eight Things To Know From Novartis' Third Quarter Call

The company's $2.1bn acquisition of Endocyte and expansion into radiopharmaceuticals dominated some of the call, but with the launches of drugs like Cosentyx, Kymriah, Kisqali and Aimovig underway, there was a lot for Novartis' management team to address.

Sales & Earnings Launches

Novartis Tunes Into Radiopharmaceuticals With Endocyte Buy

Endocyte paid just $12m upfront a year ago for a potential first-in-class investigational radioligand therapy for prostate cancer. Novartis is buying Endocyte for a whopping $2.1bn., highlighting the company's emphasis on building in radiopharmaceuticals.

M & A Cancer
See All

Company Information

  • Industry
  • Biotechnology
    • Pharmacogenetics-Pharmacogenomics
  • In Vitro Diagnostics
  • Medical Devices
    • Diagnostic Imaging Equipment & Supplies
  • Pharmaceuticals
    • Drug Delivery
    • Radiopharmaceuticals, Contrast Agents
  • Therapeutic Areas
  • Cancer
  • Inflammation
  • Alias(es)
  • Ownership
  • Public
  • Headquarters
  • Worldwide
    • North America
      • USA
  • Parent & Subsidiaries
  • Endocyte Inc.
  • Senior Management
  • Michael A Sherman, Pres. & CEO
    Michael T Andriole, CFO
    Matthew Call, VP, Bus. Dev. & Mktg.
    Philip S Low, PhD, CSO
    Alison A Armour, MD, CMO
  • Contact Info
  • Endocyte Inc.
    Phone: (765) 463-7175
    3000 Kent Ave.
    Ste. A1-100
    West Lafayette, IN 47906
    USA
Advertisement
Advertisement
UsernamePublicRestriction

Register